BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology. 2015;149:883-885.e9. [PMID: 26164495 DOI: 10.1053/j.gastro.2015.06.043] [Cited by in Crossref: 162] [Cited by in F6Publishing: 152] [Article Influence: 23.1] [Reference Citation Analysis]
Number Citing Articles
1 Piggott DA, Tuddenham S. The gut microbiome and frailty. Transl Res 2020;221:23-43. [PMID: 32360945 DOI: 10.1016/j.trsl.2020.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Bajinka O, Tan Y, Abdelhalim KA, Özdemir G, Qiu X. Extrinsic factors influencing gut microbes, the immediate consequences and restoring eubiosis. AMB Express 2020;10:130. [PMID: 32710186 DOI: 10.1186/s13568-020-01066-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhou J, Shrestha P, Qiu Z, Harman DG, Teoh WC, Al-Sohaily S, Liem H, Turner I, Ho V. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma. J Clin Med. 2020;9. [PMID: 32650561 DOI: 10.3390/jcm9072162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Elmunzer BJ, Wolf BJ, Scheiman JM, Tierney WM, Taylor JR; North American Alliance for the Study of Digestive Manifestations of COVID-19. Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19. Gastroenterology 2021;160:1417-1422.e14. [PMID: 33189702 DOI: 10.1053/j.gastro.2020.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Castellani C, Singer G, Kashofer K, Huber-Zeyringer A, Flucher C, Kaiser M, Till H. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol. 2017;7:444. [PMID: 29075620 DOI: 10.3389/fcimb.2017.00444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
6 Butler MI, Bastiaanssen TFS, Long-Smith C, Berding K, Morkl S, Cusack AM, Strain C, Busca K, Porteous-Allen P, Claesson MJ, Stanton C, Cryan JF, Allen D, Dinan TG. Recipe for a Healthy Gut: Intake of Unpasteurised Milk Is Associated with Increased Lactobacillus Abundance in the Human Gut Microbiome. Nutrients 2020;12:E1468. [PMID: 32438623 DOI: 10.3390/nu12051468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhang Z, Curran G, Altinok Dindar D, Wu Y, Wu H, Sharpton T, Zhao L, Lieberman D, Otaki F. Insights Into the Oral Microbiome and Barrett's Esophagus Early Detection: A Narrative Review. Clin Transl Gastroenterol 2021;12:e00390. [PMID: 34446641 DOI: 10.14309/ctg.0000000000000390] [Reference Citation Analysis]
8 Marks SL, Kook PH, Papich MG, Tolbert MK, Willard MD. ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. J Vet Intern Med 2018;32:1823-40. [PMID: 30378711 DOI: 10.1111/jvim.15337] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
9 Watanabe K, Shimodaira Y, Takahashi S, Fukuda S, Koizumi S, Matsuhashi T, Iijima K. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection. Am J Gastroenterol 2021;116:1632-7. [PMID: 33989224 DOI: 10.14309/ajg.0000000000001309] [Reference Citation Analysis]
10 Garg M, Leach ST, Pang T, Needham B, Coffey MJ, Katz T, Strachan R, Widger J, Field P, Belessis Y, Chuang S, Day AS, Jaffe A, Ooi CY. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old.J Cyst Fibros. 2018;17:109-113. [PMID: 28754328 DOI: 10.1016/j.jcf.2017.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, Steichen O, Hanslik T. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Netw Open 2019;2:e1916205. [PMID: 31774521 DOI: 10.1001/jamanetworkopen.2019.16205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
12 Duncan DR, Rosen RL. Current Insights into the Pharmacologic and Nonpharmacologic Management of Gastroesophageal Reflux in Infants. NeoReviews 2016;17:e203-12. [DOI: 10.1542/neo.17-4-e203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Barssoum K, Altibi AM, Rai D, Kharsa A, Kumar A, Chowdhury M, Elkaryoni A, Abuzaid AS, Baibhav B, Parikh V, Masri A, Amsallem M, Nanda NC. Assessment of right ventricular function following left ventricular assist device (LVAD) implantation-The role of speckle-tracking echocardiography: A meta-analysis. Echocardiography 2020;37:2048-60. [PMID: 33084128 DOI: 10.1111/echo.14884] [Reference Citation Analysis]
14 Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol 2016;32:452-60. [PMID: 27607343 DOI: 10.1097/MOG.0000000000000308] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
15 Wauters L, Tito RY, Ceulemans M, Lambaerts M, Accarie A, Rymenans L, Verspecht C, Toth J, Mols R, Augustijns P, Tack J, Vanuytsel T, Raes J. Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia. Int J Mol Sci 2021;22:13609. [PMID: 34948413 DOI: 10.3390/ijms222413609] [Reference Citation Analysis]
16 Rameau A, Andreadis K, Bayoumi A, Kaufman M, Belafsky P. Side Effects of Proton Pump Inhibitors: What are Patients’ Concerns? Journal of Voice 2021;35:809.e15-20. [DOI: 10.1016/j.jvoice.2020.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ducarmon QR, Zwittink RD, Hornung BVH, van Schaik W, Young VB, Kuijper EJ. Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. Microbiol Mol Biol Rev 2019;83:e00007-19. [PMID: 31167904 DOI: 10.1128/MMBR.00007-19] [Cited by in Crossref: 78] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]
18 Wurm P, Spindelboeck W, Krause R, Plank J, Fuchs G, Bashir M, Petritsch W, Halwachs B, Langner C, Högenauer C, Gorkiewicz G. Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion. Crit Care Med 2017;45:e600-6. [PMID: 28333760 DOI: 10.1097/CCM.0000000000002310] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
19 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
20 Gould CV, File TM Jr, McDonald LC. Causes, Burden, and Prevention of Clostridium difficile Infection. Infect Dis Clin Pract (Baltim Md) 2015;23:281-8. [PMID: 31048951 DOI: 10.1097/IPC.0000000000000331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
21 Duan J, Huang Y, Tan X, Chai T, Wu J, Zhang H, Li Y, Hu X, Zheng P, Ji P, Zhao L, Yang D, Fang L, Song J, Xie P. Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment. Transl Psychiatry 2021;11:303. [PMID: 34016954 DOI: 10.1038/s41398-021-01428-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
23 van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019;10:310. [PMID: 30659181 DOI: 10.1038/s41467-019-08294-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 42.3] [Reference Citation Analysis]
24 Chandran S, Anand AJ, Rajadurai VS, Seyed ES, Khoo PC, Chua MC. Evidence-Based Practices Reduce Necrotizing Enterocolitis and Improve Nutrition Outcomes in Very Low-Birth-Weight Infants. JPEN J Parenter Enteral Nutr 2021;45:1408-16. [PMID: 33296087 DOI: 10.1002/jpen.2058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Blesl A, Jüngst C, Lammert F, Fauler G, Rainer F, Leber B, Feldbacher N, Stromberger S, Wildburger R, Spindelböck W, Fickert P, Horvath A, Stadlbauer V. Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study. Nutrients 2020;12:E2728. [PMID: 32906634 DOI: 10.3390/nu12092728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lee P, Fike D, Yang H, Hall RG 2nd, Pass S, Alvarez CA. Do the types and routes of proton pump inhibitor treatments affect clostridium difficile in ICU patients? A retrospective cohort study. Expert Rev Clin Pharmacol 2021;14:399-404. [PMID: 33576287 DOI: 10.1080/17512433.2021.1890582] [Reference Citation Analysis]
27 Huan H, Ren T, Xu L, Hu H, Liu C. Compositional distinction of gut microbiota between Han Chinese and Tibetan populations with liver cirrhosis. PeerJ 2021;9:e12142. [PMID: 34616612 DOI: 10.7717/peerj.12142] [Reference Citation Analysis]
28 Mohandas S, Soma VL, Tran TDB, Sodergren E, Ambooken T, Goldman DL, Weinstock G, Herold BC. Differences in Gut Microbiome in Hospitalized Immunocompetent vs. Immunocompromised Children, Including Those With Sickle Cell Disease. Front Pediatr 2020;8:583446. [PMID: 33282798 DOI: 10.3389/fped.2020.583446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Drall KM, Tun HM, Kozyrskyj AL. Commentary: The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol 2018;8:430. [PMID: 30619776 DOI: 10.3389/fcimb.2018.00430] [Reference Citation Analysis]
30 Ross CL, Spinler JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe 2016;41:37-43. [PMID: 27180006 DOI: 10.1016/j.anaerobe.2016.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
31 Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol. 2016;9:606-625. [PMID: 27366227 DOI: 10.1177/1756283x16644242] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
32 Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 2016;4:12. [PMID: 26975510 DOI: 10.1186/s40168-016-0156-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
33 Kummen M, Solberg OG, Storm-Larsen C, Holm K, Ragnarsson A, Trøseid M, Vestad B, Skårdal R, Yndestad A, Ueland T, Svardal A, Berge RK, Seljeflot I, Gullestad L, Karlsen TH, Aaberge L, Aukrust P, Hov JR. Rosuvastatin alters the genetic composition of the human gut microbiome. Sci Rep 2020;10:5397. [PMID: 32214138 DOI: 10.1038/s41598-020-62261-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505-526. [PMID: 31990420 DOI: 10.1111/apt.15604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
35 Haran JP, McCormick BA. Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease. Gastroenterology 2021;160:507-23. [PMID: 33307030 DOI: 10.1053/j.gastro.2020.09.060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Marlicz W, Koulaouzidis A, Loniewski I, Koulaouzidis G. Letter by Marlicz et al Regarding Article, "Proton Pump Inhibitors Accelerate Endothelial Senescence". Circ Res 2016;119:e31-2. [PMID: 27390341 DOI: 10.1161/CIRCRESAHA.116.309157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
37 Quigley EMM, Gajula P. Recent advances in modulating the microbiome. F1000Res 2020;9:F1000 Faculty Rev-46. [PMID: 32047611 DOI: 10.12688/f1000research.20204.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
38 Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53:27-36. [PMID: 28770351 DOI: 10.1007/s00535-017-1371-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 12.0] [Reference Citation Analysis]
39 Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, Claesson MJ, Targownik LE. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:974-984. [PMID: 26923470 DOI: 10.1111/apt.13568] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
40 Snider EJ, Freedberg DE, Abrams JA. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2016;61:2217-2225. [PMID: 27068172 DOI: 10.1007/s10620-016-4155-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
41 Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res 2018;16:609-18. [PMID: 30301329 DOI: 10.5217/ir.2018.00044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Bosman W, Hoenderop JGJ, de Baaij JHF. Genetic and drug-induced hypomagnesemia: different cause, same mechanism. Proc Nutr Soc 2021;80:327-38. [PMID: 33906702 DOI: 10.1017/S0029665121000926] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Wong SH, Yu J. Proton-pump inhibitor use before fecal microbiota transplant: A wonder drug, a necessary evil, or a needless prescription? J Gastroenterol Hepatol 2020;35:913-4. [PMID: 32537754 DOI: 10.1111/jgh.15103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018;93:240-246. [PMID: 29406201 DOI: 10.1016/j.mayocp.2017.10.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 26.3] [Reference Citation Analysis]
45 Saeed M, Shoaib A, Kandimalla R, Javed S, Almatroudi A, Gupta R, Aqil F. Microbe-based therapies for colorectal cancer: Advantages and limitations. Semin Cancer Biol 2021:S1044-579X(21)00148-6. [PMID: 34020027 DOI: 10.1016/j.semcancer.2021.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lee C, Hong SN. Does Long-Term Proton Pump Inhibitor Therapy Affect the Health of Gut Microbiota? Gut Liver 2016;10:865-6. [PMID: 27784840 DOI: 10.5009/gnl16438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
47 Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction.Gastroenterology. 2017;152:1671-1678. [PMID: 28192102 DOI: 10.1053/j.gastro.2016.12.048] [Cited by in Crossref: 175] [Cited by in F6Publishing: 172] [Article Influence: 35.0] [Reference Citation Analysis]
48 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153:35-48. [PMID: 28528705 DOI: 10.1053/j.gastro.2017.04.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 146] [Article Influence: 39.6] [Reference Citation Analysis]
49 Yuzuriha K, Yakabe K, Nagai H, Li S, Zendo T, Zai K, Kishimura A, Hase K, Kim YG, Mori T, Katayama Y. Protection of gut microbiome from antibiotics: development of a vancomycin-specific adsorbent with high adsorption capacity. Biosci Microbiota Food Health 2020;39:128-36. [PMID: 32775131 DOI: 10.12938/bmfh.2020-002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Lin YT, Lin TY, Hung SC, Liu PY, Hung WC, Tsai WC, Tsai YC, Delicano RA, Chuang YS, Kuo MC, Chiu YW, Wu PH. Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers. J Pers Med 2021;11:198. [PMID: 33809103 DOI: 10.3390/jpm11030198] [Reference Citation Analysis]
51 Jang S, Lebwohl B, Abrams JA, Green PHR, Freedberg DE, Alaedini A. Celiac disease serology and gut microbiome following proton pump inhibitor treatment. Medicine (Baltimore) 2020;99:e21488. [PMID: 32871870 DOI: 10.1097/MD.0000000000021488] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Garg M, Ooi CY. The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy. Curr Gastroenterol Rep. 2017;19:6. [PMID: 28155088 DOI: 10.1007/s11894-017-0546-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
53 Rajilic-Stojanovic M, Figueiredo C, Smet A, Hansen R, Kupcinskas J, Rokkas T, Andersen L, Machado JC, Ianiro G, Gasbarrini A, Leja M, Gisbert JP, Hold GL. Systematic review: gastric microbiota in health and disease. Aliment Pharmacol Ther 2020;51:582-602. [PMID: 32056247 DOI: 10.1111/apt.15650] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
54 Otremba I, Wilczyński K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging 2016;11:397-405. [PMID: 27103793 DOI: 10.2147/CIA.S103349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, Khoruts A, Geis E, Maldonado J, McDonough-Means S, Pollard EL, Roux S, Sadowsky MJ, Lipson KS, Sullivan MB, Caporaso JG, Krajmalnik-Brown R. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5:10. [PMID: 28122648 DOI: 10.1186/s40168-016-0225-7] [Cited by in Crossref: 466] [Cited by in F6Publishing: 404] [Article Influence: 93.2] [Reference Citation Analysis]
56 De Roo AC, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg 2020;33:49-57. [PMID: 32104156 DOI: 10.1055/s-0040-1701229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
57 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
58 Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans. Endocrine Reviews 2018;39:133-53. [DOI: 10.1210/er.2017-00192] [Cited by in Crossref: 111] [Cited by in F6Publishing: 103] [Article Influence: 22.2] [Reference Citation Analysis]
59 Tasnim S, Miller AL, Jupiter DC, Hamilton CF, Reep GL, Krill TS, Pyles RB, Okereke IC. Effects of proton pump inhibitor use on the esophageal microbial community. BMC Gastroenterol 2020;20:312. [PMID: 32967615 DOI: 10.1186/s12876-020-01460-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
60 Shi Y, Li J, Yang P, Niu Z, Wei L, Chen L, Gao L. Colchicine increases intestinal permeability, suppresses inflammatory responses, and alters gut microbiota in mice. Toxicol Lett 2020;334:66-77. [PMID: 33002524 DOI: 10.1016/j.toxlet.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Wang Y, Li J, Zachariah P, Abrams J, Freedberg DE. Relationship between remote cholecystectomy and incident Clostridioides difficile infection. Clin Microbiol Infect 2019;25:994-9. [PMID: 30583059 DOI: 10.1016/j.cmi.2018.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Wu Q, Savidge TC. Systems approaches for the clinical diagnosis of Clostridioides difficile infection. Transl Res 2020;220:57-67. [PMID: 32272094 DOI: 10.1016/j.trsl.2020.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
64 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Khalili H, Axelrad JE, Roelstraete B, Olén O, D'Amato M, Ludvigsson JF. Gastrointestinal Infection and Risk of Microscopic Colitis: A Nationwide Case-Control Study in Sweden. Gastroenterology 2021;160:1599-1607.e5. [PMID: 33421519 DOI: 10.1053/j.gastro.2021.01.004] [Reference Citation Analysis]
66 Murciano-Brea J, Garcia-Montes M, Geuna S, Herrera-Rincon C. Gut Microbiota and Neuroplasticity. Cells 2021;10:2084. [PMID: 34440854 DOI: 10.3390/cells10082084] [Reference Citation Analysis]
67 Walsh J, Griffin BT, Clarke G, Hyland NP. Drug-gut microbiota interactions: implications for neuropharmacology. Br J Pharmacol 2018;175:4415-29. [PMID: 29782640 DOI: 10.1111/bph.14366] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
68 Hung T, Lee H, Tseng C, Tsai C, Tsai C. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology 2018;42:353-9. [DOI: 10.1016/j.clinre.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
69 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
70 Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C, Zhernakova A, Weersma RK. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351-358. [PMID: 28118083 DOI: 10.1080/19490976.2017.1284732] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 13.4] [Reference Citation Analysis]
71 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Kikuchi R, Irie J, Yamada-Goto N, Kikkawa E, Seki Y, Kasama K, Itoh H. The Impact of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Intestinal Microbiota Differs from that of Laparoscopic Sleeve Gastrectomy in Japanese Patients with Obesity.Clin Drug Investig. 2018;38:545-552. [PMID: 29508311 DOI: 10.1007/s40261-018-0638-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
73 Van Ameringen M, Turna J, Patterson B, Pipe A, Mao RQ, Anglin R, Surette MG. The gut microbiome in psychiatry: A primer for clinicians. Depress Anxiety 2019;36:1004-25. [PMID: 31356715 DOI: 10.1002/da.22936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
74 Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, Uhlemann AC, Lightdale CJ, Abrams JA. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28:1687-1693. [PMID: 31466948 DOI: 10.1158/1055-9965.epi-19-0008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
75 Shi YC, Cai ST, Tian YP, Zhao HJ, Zhang YB, Chen J, Ren RR, Luo X, Peng LH, Sun G, Yang YS. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease. Genomics Proteomics Bioinformatics 2019;17:52-63. [PMID: 31028880 DOI: 10.1016/j.gpb.2018.12.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
76 Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569-80. [PMID: 28087657 DOI: 10.1136/gutjnl-2016-313017] [Cited by in Crossref: 425] [Cited by in F6Publishing: 365] [Article Influence: 85.0] [Reference Citation Analysis]
77 Horvath A, Leber B, Feldbacher N, Steinwender M, Komarova I, Rainer F, Blesl A, Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep 2020;10:2723. [PMID: 32066847 DOI: 10.1038/s41598-020-59550-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
78 Schnoll-sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Curr Treat Options Gastro 2017;15:1-9. [DOI: 10.1007/s11938-017-0115-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
79 Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. Am J Gastroenterol. 2016;111:1641-1648. [PMID: 27575714 DOI: 10.1038/ajg.2016.343] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
80 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
81 Lukovic E, Moitra VK, Freedberg DE. The microbiome: implications for perioperative and critical care. Curr Opin Anaesthesiol 2019;32:412-20. [PMID: 30925514 DOI: 10.1097/ACO.0000000000000734] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
82 Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749-756. [PMID: 26719299 DOI: 10.1136/gutjnl-2015-310861] [Cited by in Crossref: 368] [Cited by in F6Publishing: 329] [Article Influence: 52.6] [Reference Citation Analysis]
83 Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD, Ang TL. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J 2019;60:512-21. [PMID: 30488079 DOI: 10.11622/smedj.2018152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
84 Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-141. [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
85 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
86 Kamareddine L, Najjar H, Sohail MU, Abdulkader H, Al-Asmakh M. The Microbiota and Gut-Related Disorders: Insights from Animal Models. Cells 2020;9:E2401. [PMID: 33147801 DOI: 10.3390/cells9112401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, Needham B, Lui K, Ali F, Day AS, Appleton L, Moeeni V, Jaffe A, Ooi CY. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros 2017;16:631-6. [PMID: 28416415 DOI: 10.1016/j.jcf.2017.03.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
88 Wurm P, Dörner E, Kremer C, Spranger J, Maddox C, Halwachs B, Harrison U, Blanchard T, Haas R, Högenauer C, Gorkiewicz G, Fricke WF. Qualitative and Quantitative DNA- and RNA-Based Analysis of the Bacterial Stomach Microbiota in Humans, Mice, and Gerbils. mSystems 2018;3:e00262-18. [PMID: 30505943 DOI: 10.1128/mSystems.00262-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
89 Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. J Clin Med 2019;8:E1108. [PMID: 31349746 DOI: 10.3390/jcm8081108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
90 Giron F, Quigley EMM. Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. J Neurogastroenterol Motil 2018;24:355-66. [PMID: 29684976 DOI: 10.5056/jnm18004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
91 van Hemert S, Skonieczna-Żydecka K, Loniewski I, Szredzki P, Marlicz W. Microscopic colitis-microbiome, barrier function and associated diseases. Ann Transl Med 2018;6:39. [PMID: 29610731 DOI: 10.21037/atm.2017.03.83] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
92 McCoubrey LE, Gaisford S, Orlu M, Basit AW. Predicting drug-microbiome interactions with machine learning. Biotechnol Adv 2021;:107797. [PMID: 34260950 DOI: 10.1016/j.biotechadv.2021.107797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Wang C, Hu Y, Yang H, Wang S, Zhou B, Bao Y, Huang Y, Luo Q, Yang C, Xie X, Yang S. Function of Non-coding RNA in Helicobacter pylori-Infected Gastric Cancer. Front Mol Biosci 2021;8:649105. [PMID: 34046430 DOI: 10.3389/fmolb.2021.649105] [Reference Citation Analysis]
94 Virili C, Centanni M. “With a little help from my friends” - The role of microbiota in thyroid hormone metabolism and enterohepatic recycling. Molecular and Cellular Endocrinology 2017;458:39-43. [DOI: 10.1016/j.mce.2017.01.053] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
95 Hov JR. Editorial: proton pump inhibition - microbial complications beyond dysbiosis. Aliment Pharmacol Ther 2019;50:962-3. [PMID: 31591776 DOI: 10.1111/apt.15495] [Reference Citation Analysis]
96 Kostrzewska M, Świdnicka-Siergiejko A, Olszańska D, Jurkowska G, Garley M, Ratajczak-Wrona W, Jabłońska E, Jamiołkowski J, Dabrowski A. The effect of omeprazole treatment on the gut microflora and neutrophil function. Clin Res Hepatol Gastroenterol 2017;41:575-84. [PMID: 28258834 DOI: 10.1016/j.clinre.2017.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
97 Quigley EM. Basic Definitions and Concepts: Organization of the Gut Microbiome. Gastroenterol Clin North Am 2017;46:1-8. [PMID: 28164844 DOI: 10.1016/j.gtc.2016.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
98 Walker AW, Flint HJ. Editorial: further evidence that proton pump inhibitors may impact on the gut microbiota. Aliment Pharmacol Ther 2016;43:1104-5. [PMID: 27072320 DOI: 10.1111/apt.13596] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018;97:195-204. [PMID: 29316555 DOI: 10.1159/000481813] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
100 Ihekweazu FD, Versalovic J. Development of the Pediatric Gut Microbiome: Impact on Health and Disease. Am J Med Sci 2018;356:413-23. [PMID: 30384950 DOI: 10.1016/j.amjms.2018.08.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
101 Elias E, Targownik LE. The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 2019;79:715-31. [PMID: 30972661 DOI: 10.1007/s40265-019-01110-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
102 Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: An age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100-105. [PMID: 29371761 DOI: 10.3164/jcbn.17-78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
103 Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
104 Qi C, Wang P, Fu T, Lu M, Cai Y, Chen X, Cheng L. A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases. Brief Funct Genomics 2021;20:42-60. [PMID: 33554248 DOI: 10.1093/bfgp/elaa029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
105 Dharmaratne P, Rahman N, Leung A, Ip M. Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis. Ann Med 2021;53:662-81. [PMID: 34170204 DOI: 10.1080/07853890.2021.1927170] [Reference Citation Analysis]
106 Kayar Dogan E, Abaci Gunyar O, Topal F, Alper E, Ekinci N. Bacterial species and total bacterial load in the distal oesophagus in patients with and without clinical gastric reflux. J Appl Microbiol 2019;126:1891-8. [PMID: 30873693 DOI: 10.1111/jam.14250] [Reference Citation Analysis]
107 Lagier J. Gut microbiota and Clostridium difficile infections. Human Microbiome Journal 2016;2:10-4. [DOI: 10.1016/j.humic.2016.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
108 Mishiro T, Oka K, Kuroki Y, Takahashi M, Tatsumi K, Saitoh T, Tobita H, Ishimura N, Sato S, Ishihara S, Sekine J, Wada K, Kinoshita Y. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:1059-1066. [PMID: 29105152 DOI: 10.1111/jgh.14040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
109 Vasapolli R, Schütte K, Schulz C, Vital M, Schomburg D, Pieper DH, Vilchez-Vargas R, Malfertheiner P. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology 2019;157:1081-1092.e3. [PMID: 31175864 DOI: 10.1053/j.gastro.2019.05.068] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
110 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Ventura M, Meschi T. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 2017;7:11102. [PMID: 28894183 DOI: 10.1038/s41598-017-10734-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 16.6] [Reference Citation Analysis]
111 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
112 Lin YT, Lin TY, Hung SC, Liu PY, Wu PH, Chuang YS, Hung WC, Chiu YW, Kuo MC, Wu CY. Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients. Microorganisms 2021;9:286. [PMID: 33573326 DOI: 10.3390/microorganisms9020286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Mohammadkhah AI, Simpson EB, Patterson SG, Ferguson JF. Development of the Gut Microbiome in Children, and Lifetime Implications for Obesity and Cardiometabolic Disease. Children (Basel) 2018;5:E160. [PMID: 30486462 DOI: 10.3390/children5120160] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
114 Lee SM, Kim N, Nam RH, Park JH, Choi SI, Park YT, Kim YR, Seok YJ, Shin CM, Lee DH. Gut microbiota and butyrate level changes associated with the long-term administration of proton pump inhibitors to old rats. Sci Rep 2019;9:6626. [PMID: 31036935 DOI: 10.1038/s41598-019-43112-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
115 Schmidt TSB, Raes J, Bork P. The Human Gut Microbiome: From Association to Modulation. Cell 2018;172:1198-215. [PMID: 29522742 DOI: 10.1016/j.cell.2018.02.044] [Cited by in Crossref: 285] [Cited by in F6Publishing: 238] [Article Influence: 95.0] [Reference Citation Analysis]
116 Pascale A, Marchesi N, Govoni S, Barbieri A. Targeting the microbiota in pharmacology of psychiatric disorders. Pharmacol Res 2020;157:104856. [PMID: 32389857 DOI: 10.1016/j.phrs.2020.104856] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
117 Tomkovich S, Lesniak NA, Li Y, Bishop L, Fitzgerald MJ, Schloss PD. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model. mSphere 2019;4:e00693-19. [PMID: 31748246 DOI: 10.1128/mSphere.00693-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
118 Pasman EA, Ong B, Witmer CP, Nylund CM. Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly. Curr Allergy Asthma Rep 2020;20:39. [PMID: 32524278 DOI: 10.1007/s11882-020-00926-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Wang X, Tang Q, Hou H, Zhang W, Li M, Chen D, Gu Y, Wang B, Hou J, Liu Y, Cao H. Gut Microbiota in NSAID Enteropathy: New Insights From Inside. Front Cell Infect Microbiol 2021;11:679396. [PMID: 34295835 DOI: 10.3389/fcimb.2021.679396] [Reference Citation Analysis]
120 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
121 Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol 2018;25:243-52. [PMID: 30320163 DOI: 10.1159/000487154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
122 Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018;9:432-45. [PMID: 29705929 DOI: 10.1007/s13238-018-0547-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
123 Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease. Curr Neuropharmacol 2021;19:233-47. [PMID: 32504503 DOI: 10.2174/1570159X18666200606233050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
124 Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 2017;74:2959-77. [PMID: 28352996 DOI: 10.1007/s00018-017-2509-x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 26.6] [Reference Citation Analysis]
125 Ricord M, Andrews FM, Yñiguez FJM, Keowen M, Garza F Jr, Paul L, Chapman A, Banse HE. Impact of concurrent treatment with omeprazole on phenylbutazone-induced equine gastric ulcer syndrome (EGUS). Equine Vet J 2021;53:356-63. [PMID: 32697849 DOI: 10.1111/evj.13323] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
126 Haran JP, Bhattarai SK, Foley SE, Dutta P, Ward DV, Bucci V, McCormick BA. Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway. mBio 2019;10:e00632-19. [PMID: 31064831 DOI: 10.1128/mBio.00632-19] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 28.3] [Reference Citation Analysis]
127 Haran JP, Ward DV, Bhattarai SK, Loew E, Dutta P, Higgins A, McCormick BA, Bucci V. The high prevalence of Clostridioides difficile among nursing home elders associates with a dysbiotic microbiome. Gut Microbes 2021;13:1-15. [PMID: 33764826 DOI: 10.1080/19490976.2021.1897209] [Reference Citation Analysis]
128 Chan FK. Do Proton Pump Inhibitors Exacerbate Nonsteroidal Anti-Inflammatory Drug-Induced Small-Bowel Enteropathy? Clinical Gastroenterology and Hepatology 2016;14:816-7. [DOI: 10.1016/j.cgh.2016.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
129 Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, Yamashiro Y, Watanabe S. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors. Dig Dis Sci. 2018;63:2940-2949. [PMID: 29796911 DOI: 10.1007/s10620-018-5122-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
130 Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2017;17:94. [PMID: 29039142 DOI: 10.1007/s11910-017-0802-6] [Cited by in Crossref: 205] [Cited by in F6Publishing: 185] [Article Influence: 41.0] [Reference Citation Analysis]
131 Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, Chan PA, Mylonakis E, Fuchs BB, Belenky P. The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization. Sci Rep 2017;7:11040. [PMID: 28887570 DOI: 10.1038/s41598-017-11427-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
132 Hazzan R, Darawsha U, Neeman Z, Aviv A. Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Expert Rev Hematol 2021;14:503-7. [PMID: 33899663 DOI: 10.1080/17474086.2021.1920011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Mougey EB, Nguyen V, Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Borrell B, Román E, González-Lois C, Chao M, Al-Atrash H, Franciosi JP. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31129-0. [PMID: 32798708 DOI: 10.1016/j.cgh.2020.08.020] [Reference Citation Analysis]
134 Cohen ME, Hathway JM, Salmasian H, Liu J, Terry M, Abrams JA, Freedberg DE. Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit. Clin Gastroenterol Hepatol. 2017;15:1030-1036.e1. [PMID: 28110095 DOI: 10.1016/j.cgh.2016.12.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
135 Aydin Ö, Nieuwdorp M, Gerdes V. The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. Curr Diab Rep 2018;18:55. [PMID: 29931613 DOI: 10.1007/s11892-018-1020-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
136 Tranberg A, Samuelsson C, Klarin B. Disturbance in the oropharyngeal microbiota in relation to antibiotic and proton pump inhibitor medication and length of hospital stay. APMIS 2021;129:14-22. [PMID: 32981186 DOI: 10.1111/apm.13087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510-9. [PMID: 32409589 DOI: 10.1136/gutjnl-2019-320204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
138 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
139 Maier L, Typas A. Systematically investigating the impact of medication on the gut microbiome. Curr Opin Microbiol 2017;39:128-35. [PMID: 29169088 DOI: 10.1016/j.mib.2017.11.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
140 Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152:706-715. [PMID: 28257716 DOI: 10.1053/j.gastro.2017.01.031] [Cited by in Crossref: 322] [Cited by in F6Publishing: 270] [Article Influence: 64.4] [Reference Citation Analysis]
141 Hong S, Lee E, Shin J. Proton‐pump inhibitors and the risk of Clostridium difficile –associated diarrhea in high‐risk antibiotics users: A population‐based case‐crossover study. Pharmacoepidemiol Drug Saf 2019;28:479-88. [DOI: 10.1002/pds.4745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
142 Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2018;12:899-906. [PMID: 30040500 DOI: 10.1080/17474124.2018.1503946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
143 van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
144 Dos Santos-Schaller O, Boisset S, Seigneurin A, Epaulard O. Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy. Springerplus 2016;5:430. [PMID: 27104118 DOI: 10.1186/s40064-016-2058-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
145 Duncan DR, Mitchell PD, Larson K, McSweeney ME, Rosen RL. Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. JAMA Otolaryngol Head Neck Surg 2018;144:1116-24. [PMID: 30325987 DOI: 10.1001/jamaoto.2018.1919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
146 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
147 Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? Intern Med J 2019;49:694-701. [PMID: 30719802 DOI: 10.1111/imj.14241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Debelius J, Song SJ, Vazquez-Baeza Y, Xu ZZ, Gonzalez A, Knight R. Tiny microbes, enormous impacts: what matters in gut microbiome studies? Genome Biol 2016;17:217. [PMID: 27760558 DOI: 10.1186/s13059-016-1086-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
149 Duncan DR, Larson K, Rosen RL. Clinical Aspects of Thickeners for Pediatric Gastroesophageal Reflux and Oropharyngeal Dysphagia. Curr Gastroenterol Rep 2019;21:30. [PMID: 31098722 DOI: 10.1007/s11894-019-0697-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
150 Koch CD, Gladwin MT, Freeman BA, Lundberg JO, Weitzberg E, Morris A. Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radic Biol Med 2017;105:48-67. [PMID: 27989792 DOI: 10.1016/j.freeradbiomed.2016.12.015] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
151 Kienesberger B, Obermüller B, Singer G, Mittl B, Grabherr R, Mayrhofer S, Heinl S, Stadlbauer V, Horvath A, Miekisch W, Fuchs P, Klymiuk I, Till H, Castellani C. (S)-Reutericyclin: Susceptibility Testing and In Vivo Effect on Murine Fecal Microbiome and Volatile Organic Compounds. Int J Mol Sci 2021;22:6424. [PMID: 34203988 DOI: 10.3390/ijms22126424] [Reference Citation Analysis]
152 Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017;106:171-181. [PMID: 26875998 DOI: 10.1016/j.micpath.2016.02.005] [Cited by in Crossref: 358] [Cited by in F6Publishing: 339] [Article Influence: 59.7] [Reference Citation Analysis]
153 Melgar S, Nieuwdorp M. Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health? Gastroenterology 2015;149:848-50. [PMID: 26306767 DOI: 10.1053/j.gastro.2015.08.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
154 Takashima S, Tanaka F, Kawaguchi Y, Usui Y, Fujimoto K, Nadatani Y, Otani K, Hosomi S, Nagami Y, Kamata N, Taira K, Tanigawa T, Watanabe T, Imoto S, Uematsu S, Fujiwara Y. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. Neurogastroenterol Motil 2020;32:e13841. [PMID: 32319196 DOI: 10.1111/nmo.13841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
155 Mössner J. The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int 2016;113:477-83. [PMID: 27476707 DOI: 10.3238/arztebl.2016.0477] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
156 Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018;47:332-45. [PMID: 29205415 DOI: 10.1111/apt.14451] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 18.8] [Reference Citation Analysis]